Yarrow Bioscience (YARW) Short term Debt (2020 - 2021)
Yarrow Bioscience's (YARW) quarterly Short term Debt came in at $33.4 million in Q2 2021, up 69.97% on a QoQ basis from $19.6 million in Q1 2020.
Yarrow Bioscience (YARW) Short term Debt (2020 - 2021) Analysis & Trends
Yarrow Bioscience (YARW) has 2 years of Short term Debt data on file, last reported at $33.4 million in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Yarrow Bioscience | 31.25 Mn | 8.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 33.38 Mn |
| Mar 31, 2020 | 19.64 Mn |